Status:
NOT_YET_RECRUITING
Nerve Conduction Study for Assessment of Peripheral Neuropathy in Rheumatoid Arthritis Patients on the Janus Kinase Inhibitor Baricitinib
Lead Sponsor:
Sohag University
Conditions:
Rheumatoid Arthritis
Eligibility:
All Genders
18-65 years
Phase:
NA
Brief Summary
Rheumatoid arthritis is a chronic, systemic, autoimmune inflammatory disease that mainly affects the joints and periarticular soft tissues. Baricitinib (Olumiant®) is an oral, targeted synthetic DMARD...
Eligibility Criteria
Inclusion
- Patients fulfill the 2010 ACR/EULAR classification criteria of RA
- Age above 18 years old.
- Patient cooperative and can answer questions
Exclusion
- Other rheumatologic or collagen diseases.
- Age below 18 years and above 65 years.
- Uncooperative patients.
- Patients with other causes of peripheral neuropathy as Diabetes mellitus.
Key Trial Info
Start Date :
May 1 2025
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
November 1 2025
Estimated Enrollment :
60 Patients enrolled
Trial Details
Trial ID
NCT06977035
Start Date
May 1 2025
End Date
November 1 2025
Last Update
May 16 2025
Active Locations (0)
Enter a location and click search to find clinical trials sorted by distance.
No Results Found
We couldn’t find results for the location/zipcode entered or within the selected range. Please check your input or adjust your search.